- Fumikazu Wanibuchi (Ph.D.),President & CEO and Vice president of Clinical Development
- Philip Davy (Ph.D.), Global Head of Business Development, and President & CEO of Braizon Therapeutics US,Inc
- Masato Chiba (Ph.D.),Vice president of Research and Development
- TTakanobu Nishikido (CPA),Vice president of Business Adminstration & Finance
President & CEO and Vice president of Clinical Development
Breakthrough to overcome the difficulties in drug discovery and development in neuroscience area
I had been working on drug discovery, clinical development and project management in CNS and Pain Therapeutic Areas focused on neuroscience in Astellas Pharma Inc. for more than 30 years. As you know, drug discovery and development in neuroscience is extremely difficult to provide new first-in-class medicines. Based on such a background, I believe that innovative science and technology of Braizon Therapeutics Inc. must be a breakthrough to overcome the difficulties in drug discovery and development in neuroscience area.
Recently, brain itself and brain function have been elucidated gradually due to remarkable progress of neuroscience. A much greater understanding of pathophysiology in brain and CNS diseases has been developed. However, overcoming the diseases themselves has not been achieved yet and one of high hurdles is blood-brain-barrier. “Brain” made “barrier” to protect brain itself against transition of substances from peripheral blood. Namely, proteins, antibodies and oligonucleotides as drug candidates cannot penetrate at all. Even low molecule drugs are often difficult to penetrate with enough brain concentrations. We, Braizon is making every effort to utilize practically this innovative DDS technology. In future, we will provide innovative medicines to patients suffering from CNS diseases.
Global Head of Business Development, and President & CEO of Braizon Therapeutics US, Inc
Strong passion for collaborative success
Braizon brings together innovative delivery technology with the promising developments of external partners to build novel therapeutic options for CNS disorders, founded on strong collaborations. Already operating in Japan and the U.S.A., Team Braizon is expanding our partnerships to facilitate research and development of new CNS therapies globally.
My own strong interest in the biology of aging, and interventions to extend or restore the healthy lives of older adults, attracted me to this company. A research career in bioengineering with a focus on cellular and small molecule translational therapies left me with concerns about the slow pace of development for new therapy options for the brain.
Braizon’s drug delivery system is versatile enough for many modalities of therapy to enter the CNS. We have a collaborative and open approach to development that enables any interested partners in the Pharmaceutical and Biotechnology industries to benefit from our highly efficiency portal to the CNS. The drive to continually innovate, wealth of drug development experience, and passion to help people in need of new and better options gives Team Braizon the strength and confidence to deliver on the promise of our technology.
Vice president of Research and Development
Deliver medicines for patients
For more than 30 years, I have been working on the discovery and development of new drugs for the treatments of CNS diseases and brain tumors at Drug Metabolism and Pharmacokinetics Laboratories in pharmaceutical companies within and outside Japan (Merck Research Laboratories in PA, US; Research Institutes at Banyu and Taiho Pharmaceutical Companies in Tsukuba, JAPAN). As fascinated by Braizon’s breakthrough technology conferring the ability of brain penetration to the drugs which otherwise cannot pass through blood brain barrier (BBB), I left the pharmaceutical company to join Team Braizon with the enthusiasm and passion to bring novel technology to clinical application. Data for the efficacy to the target inside brain by non-brain-penetrable compounds crossing BBB through our technology have been accumulated every day at Braizon. We have been dedicated to bringing our innovative drug delivery system based on the GLUT1-mediated transcytosis of glucose-conjugated micelle incorporating non-brain-penetrable pharmaceutical ingredients with different modality to the patients suffering from brain disease as soon as possible!
Vice president of Business Administration & Finance
Challenge in Bio with Different Industries Success
In general, there are many financial hurdles for bio-ventures to proceed pharmaceutical business and many hurdles are expected to implement Braizon technology in society.
Until now, I have been involved in management planning and management, IPO preparation, and financing for IT- related companies and manufacturing venture companies.
I have encountered various scenes. A situation where sales grew steadily and the number of employees joined and became difficult, a scene where investment failed in a new business but faced difficulties, a growth strategy failed, not going as planned, and funds were short verge of fall up to, debt financing will connect with, there was also the fact that was able to equity financing. Although the market is growing, there were times when it was difficult to draw a growth strategy due to the company’s capacity.
Among them, the reason why for joining Braizon is that the challenge of biotechnology startups and the implementation of Braizon technology that confronts diseases of the central nervous system that damage human dignity have been implemented in society.
Let’s work together. There’s no promised future. Let’s create a bright future by ourselves! Come on and join us!
Kazunori Kataoka(Ph.D., Dr.h.c.)
He earned his Ph.D. degrees from University of Tokyo.
His professional interests are focusing on synthetic chemistry, medical bioengineering, biomaterial science.
He is engaged in research and development of DDS and nanomachines applying polymer nanotechnology.
Prof. Kataoka has been the recipient of many awards, including
Humblodt Research Award, Alexander von Humboldt Foundation, Leo Esaki Prize and Gutenberg Research Award. He has been elected as a Foreign Member of the US National Academy of Engineering (NAE) and a Fellow of the US Academy of Inventors (NAI) since 2017.
Takanori Yokota(MD, Ph.D.)
Department of Neurology and Neurological Science, Tokyo Medical and Dental University
Board Certified Neurologist of the Japanese Society of Neurology
Board Certified Member of the Japanese Society of Internal Medicine
He earned his MD and Ph.D. degrees from Tokyo Medical and Dental University.
His professional interests are focusing on neurology and gene therapy with nucleic acid.
He accepted a position as Professor of Department of Neurology and Neurological Science at Tokyo Medical and Dental University in 2009 and is leading and growing the department.
Prof. Yokota has published more than 150 outstanding scientific papers and been the recipient of many awards,
including Distinction Award of American Academy of Neurology(AAN) 2018.
Please use our Contact Form to learn about current openings within Team Braizon.